Aurobindo Pharma is pushing beyond everyday generics into tougher-to-make medicines like biosimilars and specialty drugs, helped by new approvals in Europe and added capacity across its factories. The big question is whether those new businesses can grow fast enough to offset pricing pressure and regulatory setbacks—especially given the company’s heavy dependence on the U.S. market.Read more
Aurobindo Pharma faces growing pressure in its biggest markets as stricter rules, tougher inspections, and ongoing price cuts make it harder to protect profits in everyday generic medicines. The real question is whether newer, higher-value drugs, tighter control over manufacturing, and smart dealmaking can offset those headwinds—or if the squeeze keeps getting worse.Read more
Aurobindo Pharma is betting that making more of its own drug ingredients and expanding production can help it sell more and keep more profit, especially as demand grows for harder-to-make medicines. But its heavy dependence on low-cost generic drugs in the US leaves it exposed to price cuts, supply disruptions, and regulators slowing approvals.Read more
No trending discussion available.
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
